Search clinical trials for: BI 135585 XX

Total 1245 results

Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of Single Rising Doses of BI 705564 and Food Effect on BI 705564 in Healthy Male Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

Pharmacokinetics and Relative Bioavailability of 11634 Immediate Release Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

Hepatitis C, Chronic

United States, Australia, Austria, France, Germany, New Zealand, Portugal, Romania, Spain, Switzerland
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Not yet recruiting

A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body

Healthy
Boehringer Ingelheim

Recruiting

A Study in Healthy People to See How Zongertinib is Taken up Into the Blood When Given as Tablets Made by Two Different Manufacturers

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis

Psoriasis

Bulgaria, Romania, Moldova, Republic of, Georgia
Northwell Health

Recruiting

Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort

Prostate Cancer | Magnetic Resonance Imaging | Population at Risk

United States
Boehringer Ingelheim

Recruiting

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

Solid Tumors

United States, Japan, Canada
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Neoplasm Metastasis | Non-Small Cell Lung Cancer

United States, Hong Kong, Spain, Korea, Republic of, China, Israel, Germany, Japan, Singapore, Australia, United Kingdom, Austria, Netherlands, France, Portugal, Sweden, Italy, Belgium
Boehringer Ingelheim

Completed

A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder

Post-Traumatic Stress Disorder

United States, Germany, Sweden, Finland, Israel, Poland, Mexico, Croatia
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1323495 Are Taken up in the Body and How Well They Are Tolerated.

Healthy

Germany
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder

Borderline Personality Disorder

Spain, Germany, Sweden, United States, Mexico, Argentina, France, Poland, Australia, Belgium, Bulgaria, Czechia, Denmark, Italy, Japan
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated

Healthy

Belgium
Boehringer Ingelheim

Completed

Evaluation of Safety and Tolerability of BI 894416 in Patients With Mild Asthma

Asthma

Germany
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of Multiple Doses of BI 655064 in Healthy Chinese Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Terminated

This Study in Healthy Volunteers Determines the Amount of BI 730460 in the Blood When Taken as Tablet. It Looks at How Different Doses of BI 730460 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How Food Influences the Amount of BI 730460 in the Blood.

Healthy

Germany
Boehringer Ingelheim

Terminated

ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19

COVID-19

Spain, United States, Mexico, Brazil, Chile, Puerto Rico
Boehringer Ingelheim

Completed

This Study Tests the Safety, Tolerability and How Different Doses of BI 1265162 Are Taken up in the Body of Healthy Men

Healthy

Germany
Medtronic Cardiac Rhythm and Heart Failure

Completed

SelectSecure 3830 Lead Imaging

Heart Diseases

United States
Boehringer Ingelheim

Withdrawn

BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)

Lupus Erythematosus, Systemic
Boehringer Ingelheim

Withdrawn

This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated

Healthy
Boehringer Ingelheim

Withdrawn

A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis

Arthritis, Psoriatic
Boehringer Ingelheim

Completed

A Study About How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated in Healthy Japanese Men

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 764198 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 Days

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)

Diabetic Nephropathies

United States, Canada, Belgium, Czechia, Germany
Boehringer Ingelheim

Completed

BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects

Cystic Fibrosis

Germany, United Kingdom
Boehringer Ingelheim

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Safety and Tolerability of BI 685509 in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests How Healthy Men Tolerate Different Doses of BI1015550. The Study Also Tests How BI 1015550 is Taken up by the Body

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects

Healthy

Germany
Far Eastern Memorial Hospital

Unknown

Effect of Bi-ventricular Pacing on Autonomous Nervous System

Congestive Heart Failure
Boehringer Ingelheim

Completed

Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules

Hepatitis C

Japan
Boehringer Ingelheim

Completed

Single Rising Dose Study (Intravenous Infusion and Subcutaneous Injection) of BI 655064 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection

Healthy

United States
Boehringer Ingelheim

Completed

A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems

Hepatic Insufficiency

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How the Body Takes up BI 1467335

Healthy

Netherlands
Boehringer Ingelheim

Completed

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 187004 CL

Healthy

Germany
Boehringer Ingelheim

Not yet recruiting

A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food

Healthy
Boehringer Ingelheim

Recruiting

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 3006337 Are Tolerated

Healthy

Japan
University Hospital, Akershus
University of Oslo

Recruiting

Brief Intervention for Sleep Medication Misuse Among Elderly (BI-sleep)

Harmful Use of Hypnotic

Norway
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Germany, Belgium, Japan, France
Boehringer Ingelheim

Recruiting

A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

Bronchiectasis | Cystic Fibrosis

Belgium, Germany, Spain, Netherlands, United States, France, Italy
Boehringer Ingelheim

Recruiting

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors)

Solid Tumors

United States, Spain, Germany, Austria, France, Belgium
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)

Neoplasms

Spain, United States, Belgium, Japan, Netherlands, Italy
Boehringer Ingelheim

Recruiting

A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface

Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms

United States, Canada
Boehringer Ingelheim

Recruiting

This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)

Neoplasms

Belgium, Korea, Republic of, United States, Spain, Germany, Japan, Poland, Israel, Sweden, Denmark, Canada
Boehringer Ingelheim

Completed

A Study to Test How Different Doses of BI 765423 Are Taken up in the Body of Healthy Men

Healthy

Belgium

3

Subscribe